Year: 2012
Type: dissertation
Abstract: Systemic sclerosis (SSc) is a chronic fibrotic autoimmune disease of unknown etiology that affects the skin and several internal organs. Besides vascular disease and cellular immune activation, the major histopathologic hallmark of SSc is an excessive accumulation of extracellular matrix proteins released from activated fibroblasts, which destroys the physiological tissue architecture and impairs the function of the involved organs. As current approaches to treat fibrosis are of limited efficacy and therapies targeting specifically the activation of fibroblasts are not yet available, this study aimed to investigate novel molecular targets which might be effective in the future treatment of tissue fibrosis. The first part of the study focused on the involvement of serotonin (5-hydroxytryptamine, 5-HT) signaling to the pathogenesis of SSc and revealed a link between vasculopathy, platelet activation and tissue fibrosis. Mice deficient for tryptophan hydroxylase-1 were protected from fibrosis and inhibition of platelet activation efficiently reduced tissue fibrosis in different animal models. Serotonin exerted potent pro-fibrotic effects on cultured fibroblasts by activating the 5-HT2B receptor. Furthermore, an upregulation of 5-HT2B in skin of SSc patients, particularly in activated myofibroblasts, was observed by immunohistochemical analyses. Activation of 5-HT2B induced transforming growth factor β (TGFβ) signaling with a time-dependent increase in nuclear levels of phospho-Smad3, the major downstream effector of TGFβ. Targeting 5-HT2B, either pharmacologically or genetically, not only prevented fibrosis in mouse models of SSc, but potently induced regression of pre-established fibrosis. The second part of the study evaluated the role of the Notch pathway to fibroblast activation and tissue fibrosis. Increased levels of activated Notch-1 were found in lesional skin of SSc patients and in cultured SSc fibroblasts. In addition, the ligand Jagged-1 (JAG1) was found to be overexpressed in T cells of inflammatory infiltrates. Activation of the Notch pathway by recombinant JAG1 in cultured dermal fibroblasts resulted in increased collagen mRNA and protein levels. Moreover, JAG1 induced myofibroblast differentiation with elevated expression of α-smooth-muscle-actin and formation of stress fibers. Consistent with the increased activation of Notch signaling in SSc fibroblasts, inhibition of the pathway by blockade of γ-secretase reduced collagen production only in SSc but not in healthy dermal fibroblasts. In vivo, Notch-1 antisense transgenic mice were protected from fibrosis and inhibition of γ-secretase potently reduced pre-established fibrosis. In conclusion, these findings might have translational implications. As inhibitors for 5-HT2B and γ-secretase are already in clinical use or in clinical trials for other diseases, they would also be available for clinical trials in SSc patients. Indeed, a fist proof-of-concept trial with the 5-HT2 inhibitor terguride in patients with SSc achieved promising anti-fibrotic effects.
Author: Dees, Clara
Institution: Friedrich-Alexander-Universität Erlangen-Nürnberg
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Keywords: systemic sclerosis, fibrosis, molecular targets, serotonin signaling, 5-HT2B receptor, tryptophan hydroxylase 1, platelet activation, vasculopathy, TGF-beta signaling, Smad3, myofibroblast differentiation, Notch signaling, Jagged1, gamma-secretase inhibition, dermal fibroblasts, collagen synthesis
Open Access status: green
OpenAlex ID: W7047240578
